ICPT — Intercept Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $793.52m
- $713.07m
- $285.71m
- 57
- 14
- 79
- 49
Annual income statement for Intercept Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | R2020 December 31st | R2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 180 | 252 | 234 | 261 | 286 |
| Cost of Revenue | |||||
| Gross Profit | 177 | 248 | 232 | 260 | 285 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 465 | 564 | 464 | 345 | 446 |
| Operating Profit | -285 | -312 | -230 | -83.9 | -160 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -309 | -345 | -273 | -136 | -175 |
| Net Income After Taxes | -309 | -345 | -273 | -136 | -175 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -309 | -345 | -275 | -91.4 | 222 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -309 | -345 | -275 | -91.4 | 222 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -10.9 | -10.9 | -7.97 | -4.8 | -2.46 |